Cardiopulmonary complications of ergot-derivative dopamine agonists

Journal of Clinical Psychiatry

Volumn 65, Issue 10, 2004, Pages 1429-1430

  Rack, Michael J ^a   Baran, Alp Sinan ^a   Richert, Allen C ^a   Roffwarg, Howard P ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOLINE DERIVATIVE; NEUROLEPTIC AGENT; PERGOLIDE; RISPERIDONE;

CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; HUMAN; HYPERPROLACTINEMIA; LUNG FIBROSIS; NOTE; VALVULAR HEART DISEASE;

ANTIPSYCHOTIC AGENTS; BROMOCRIPTINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOLINES; HEART VALVE DISEASES; HUMANS; HYPERPROLACTINEMIA; PERGOLIDE; PULMONARY FIBROSIS; RISPERIDONE;

EID: 16544379848     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n1020b     Document Type: Letter

References (6)

1. Cavallaro R, Cocchi F, Angelone SM, et al. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry 2004;56:187-190
2. Ling LH, Ahlskog JE, Munger TM, et al. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease. Mayo Clin Proc 1999;74:371-375 (Pubitemid 29162538)
3. Rinne UK. Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease [letter]. Lancet 1981:1:44 (Pubitemid 11200351)
4. Danoff SK, Grasso ME, Terry PB, et al. Pleuropulmonary disease due to pergolide use for restless legs syndrome. Chest 2001;120:313-316 (Pubitemid 32744898)
5. Flowers CM, Racoosin JA, Lu SL, et al. The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 2003;78:730-731 (Pubitemid 36665904)
6. Bankowski BJ, Zacur HA. Dopamine agonist therapy for hyperprolactinemia. Clin Obstet Gynecol 2003;46:349-362 (Pubitemid 36859376)